



30 October 2020

## **ASX ANNOUNCEMENT**

### **MVP 2020 AGM**

Medical Developments International Limited (ASX: MVP) held its AGM on Wednesday, 28 October 2020.

For shareholders and other interested parties who were unable to attend, the proceedings can be downloaded and viewed via the following link:

<https://vimeo.com/webcastsquared/download/473298093/13cb406d2e>

*Authorised for release by MVP Company Secretary, Mark Edwards.*

#### **Further information:**

David Williams  
Chairman  
+61 414 383 593

Max Johnston  
Acting CEO  
+61 412 041 298

**About Pentrox®**

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox is now approved for sale in more than 40 countries and has been used safely and effectively for more than 40 years in Australia with more than 7 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

**About Medical Developments International Ltd**

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast-acting trauma and emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and also manufactures a range of world-leading Asthma respiratory devices.